Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (RECORD-3)
This study is ongoing, but not recruiting participants.
Study NCT00903175
Information provided by Novartis
First Received on April 24, 2009.
Last Updated on May 15, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
